Business Context and Reporting Period
This Form 8-K Current Report was filed by Tivic Health Systems, Inc. (trading symbol: TIVC) on September 18, 2024. The registrant is a Delaware corporation headquartered in Fremont, California, and is classified as an emerging growth company. The filing primarily addresses a corporate development event under Item 8.01.
Key Financial Metrics
The filing text does not provide specific financial data. As this is a Current Report regarding a specific event rather than a periodic financial report (10-K or 10-Q), there are no disclosed values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The material event reported is the receipt of approval from The Feinstein Institutes' Institutional Review Board (IRB) for the next phase of clinical work on the Company's non-invasive cervical vagus nerve stimulation approach. This approval facilitates the progression of the Company's clinical trials.
Outlook, Risks, and Management Commentary
- Management Commentary: The Company issued a press release (Exhibit 99.1) announcing the IRB approval, signaling a milestone in its clinical development program.
- Forward-Looking Statements: The report contains forward-looking statements regarding anticipated results and performance. Management notes these are based on current conditions and estimates.
- Risks and Uncertainties: The filing explicitly warns that actual results may differ materially from forward-looking statements due to known and unknown risks, uncertainties, and other factors. These risks could adversely affect the business and the accuracy of future projections.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific details on the clinical trial phase and timeline.
- Confirm the Company's current cash position and runway in the most recent 10-Q or 10-K, as this 8-K does not contain financial statements.
- Monitor subsequent filings for updates on the initiation of the clinical work following IRB approval.
- Review the risk factors section in the Company's latest periodic report for specific details on clinical trial risks.